Latest News

Faron commences enrolment in Phase II trial of traumakine to treat MOF in RAAA

Finland-based clinical stage biopharmaceutical firm Faron Pharmaceuticals has commenced enrolment in the Phase II INFORAAA clinical trial of traumakine (FP-1201-lyo) to treat patients...

Faron commences enrolment in Phase II trial of traumakine to treat MOF in RAAA

Chi-Med begins Phase II trial of savolitinib to treat PSC in China

Biopharmaceutical firm Hutchison China MediTech (Chi-Med) has begun a Phase II clinical trial of savolitinib for the treatment of locally advanced or metastatic pulmonary sarcomatoid...

Chi-Med begins Phase II trial of savolitinib to treat PSC in China

Celgene reports positive top-line results from Phase III trial of ozanimod to treat RMS

Celgene reports positive top-line results from Phase III trial of ozanimod to treat RMS

University of Liverpool and AKL collaborate to evaluate APPA for osteoarthritis

University of Liverpool and AKL collaborate to evaluate APPA for osteoarthritis

AstraZeneca announces positive results from Phase III trial of Lynparza for breast cancer

Biopharmaceutical firm AstraZeneca has announced positive results from its Phase III clinical trial (OlympiAD) of Lynparza (olaparib) to treat patients with HER2-negative metastatic breast...

AstraZeneca announces positive results from Phase III trial of Lynparza for breast cancer

Tracon commences dosing in Phase III trial of TRC105 to treat angiosarcoma

US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has commenced dosing in its Phase III trial of TRC105 in combination with Votrient (pazopanib) for the treatment of angiosarcoma....

Tracon commences dosing in Phase III trial of TRC105 to treat angiosarcoma

Deals this week: Aldeyra Therapeutics, Oncology Venture Sweden, Treos Bio

US-based biotechnology company Aldeyra Therapeutics has announced a public offering of shares of its common stock to raise funds required primarily for the continued development of its...

Deals this week: Aldeyra Therapeutics, Oncology Venture Sweden, Treos Bio

M&As this week: Inhalation Sciences, Quotient Clinical

Swedish drug development services provider Inhalation Sciences Sweden has been acquired by a consortium comprising Per Gerde, Fredrik Sjovall, and Rasunda...

M&As this week: Inhalation Sciences, Quotient Clinical

Theratechnologies reports comparative PK Data on IM and IV administration of ibalizumab in HIV patients

Pharmaceutical firm Theratechnologies has announced the pharmacokinetics (PK) and pharmacodynamics (PD) data comparing the intramuscular (IM) with the intravenous (IV) administration of...

Theratechnologies reports comparative PK Data on IM and IV administration of ibalizumab in HIV patients

Ardelyx reports positive results from Phase III trial of tenapanor for hyperphosphatemia

Ardelyx reports positive results from Phase III trial of tenapanor for hyperphosphatemia

Sanofi initiates Phase II trial of GZ/SAR402671 to treat Parkinson’s Disease with GBA gene

Sanofi's specialist care global business unit Sanofi Genzyme has initiated a Phase II trial of an investigational oral therapy GZ/SAR402671 to treat patients with Parkinson’s disease, who carry...

Sanofi initiates Phase II trial of GZ/SAR402671 to treat Parkinson’s Disease with GBA gene

Berg begins Phase I/II trial of BPM 31510-IV in patients with glioblastoma multiforme

Biopharmaceutical firm Berg has begun a Phase I/II monotherapy clinical trial of its drug candidate BPM 31510-IV to treat patients with glioblastoma multiforme...

Berg begins Phase I/II trial of BPM 31510-IV in patients with glioblastoma multiforme

Merck reports positive results from Phase III trial of doravirine to treat HIV-1

Merck reports positive results from Phase III trial of doravirine to treat HIV-1

Chi-Med begins Phase I trial of HMPL-453 in Australia for solid malignancies

Biopharmaceutical company Hutchison China MediTech (Chi-Med) has begun the first-in-human (FIH) Phase I clinical trial of HMPL-453 to treat patients with advanced or metastatic solid...

Chi-Med begins Phase I trial of HMPL-453 in Australia for solid malignancies

Progenics initiates Phase I trial of 1095 to treat metastatic prostate cancer

Progenics initiates Phase I trial of 1095 to treat metastatic prostate cancer

Sage Therapeutics reports positive top-line results from Phase II trial of SAGE-217 in MDD

Clinical-stage biopharmaceutical company Sage Therapeutics has reported positive top-line results from the Phase II clinical trial of orally administered SAGE-217 to treat patients with...

Sage Therapeutics reports positive top-line results from Phase II trial of SAGE-217 in MDD

DelMar Pharma begins dosing in Phase II trial of VAL-083 to treat GBM

DelMar Pharma begins dosing in Phase II trial of VAL-083 to treat GBM

Biotron begins Phase II trial of BIT225 to treat HIV-1

Australian-based Biotron has begun the Phase II clinical trial (BIT225-009) of its anti-viral drug BIT225 to treat patients with human immunodeficiency virus (HIV-1)...

Biotron begins Phase II trial of BIT225 to treat HIV-1

PhytoTech initiates Phase II trial of PTL101 to treat pediatric refractory epilepsy

Australian-based MMJ PhytoTech's Israeli division PhytoTech Therapeutics has initiated the Health Authorities-approved Phase II clinical trial of PTL101 capsules to treat refractory epilepsy...

PhytoTech initiates Phase II trial of PTL101 to treat pediatric refractory epilepsy

Cellceutix initiates main clinical site for Phase IIa trial of Kevetrin in ovarian cancer

US-based clinical stage biopharmaceutical firm Cellceutix has initiated its main clinical site at a Texas-based cancer centre to begin the Phase IIa clinical trial (CTIX-KEV-201) of Kevetrin...

Cellceutix initiates main clinical site for Phase IIa trial of Kevetrin in ovarian cancer

Prevacus to initiate Phase I trial of PRV-002 to treat concussion

US-based biopharmaceutical company Prevacus is planning to initiate a Phase I clinical trial of PRV-002 to treat concussion / mild traumatic brain injury (mtbi) in the first half of this...

Prevacus to initiate Phase I trial of PRV-002 to treat concussion
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_1016278895